Arbutus to Report Third Quarter 2018 Financial Results
October 31 2018 - 8:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced that it has scheduled its third quarter financial
results, conference call and webcast for Wednesday, November 7,
2018. The schedule for the press release and conference
call/webcast are as follows:
|
|
|
|
|
• |
|
Q3 2018
Press Release: |
|
November
7, 2018 at 4:00 p.m. ET |
• |
|
Q3 2018
Conference Call: |
|
November
7, 2018 at 4:30 p.m. ET |
• |
|
Domestic
Dial-In Number: |
|
1-866-393-1607 |
• |
|
International Dial-In Number: |
|
1-914-495-8556 |
• |
|
Conference ID Number: |
|
2628189 |
|
A live webcast of the conference call can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com.
An archived webcast will be available on the
Arbutus website after the event. Alternatively, you may access a
replay of the conference call by calling 1-855-859-2056 or
1-404-537-3406, and reference conference ID 2628189.
About Arbutus
Arbutus Biopharma Corporation is a
publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated
to discovering, developing, and commercializing a cure for patients
suffering from chronic Hepatitis B (HBV) infection. Arbutus is
developing multiple drug candidates, each of which have the
potential to improve upon the standard of care and contribute to a
curative combination regimen. For more information, visit
www.arbutusbio.com.
Contact Information
InvestorsMark MurrayPresident and CEOPhone:
604-419-3200 Email: ir@arbutusbio.com
MediaPam Murphy Investor Relations
ConsultantPhone: 604-419-3200Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024